AstraZeneca, Daiichi Sankyo's Enhertu rings up success in another breast cancer trial
Less than three weeks after AstraZeneca and Daiichi Sankyo reported positive results for oncology powerhouse Enhertu in a first-line breast cancer trial, the companies have scored again in a phase 3 trial in early breast cancer.
Less than three weeks after AstraZeneca and Daiichi Sankyo reported positive results for oncology powerhouse Enhertu in a first-line breast cancer trial, the companies have scored again in a phase 3 trial in early breast cancer.
